Tag: nasdaq

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 20, 2024 17:00 ET  | Source: Iovance Biotherapeutics, Inc. SAN CARLOS,…

GlobeNews Wire GlobeNews Wire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 20, 2024 16:30 ET  | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…

GlobeNews Wire GlobeNews Wire

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

December 20, 2024 17:00 ET  | Source: Iovance Biotherapeutics, Inc. SAN CARLOS,…

GlobeNews Wire GlobeNews Wire

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 20, 2024 16:30 ET  | Source: Ultragenyx Pharmaceutical Inc. NOVATO, Calif.,…

GlobeNews Wire GlobeNews Wire

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

December 12, 2024 20:00 ET | Source: Mainz BioMed NV BERKELEY, Calif.…

GlobeNews Wire GlobeNews Wire

Cerence AI Announces Equity Grant to Employee Under Inducement Plan Pursuant to Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC)…

GlobeNews Wire GlobeNews Wire

Cerence AI Announces Equity Grant to Employee Under Inducement Plan Pursuant to Nasdaq Listing Rule 5635(c)(4)

BURLINGTON, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC)…

GlobeNews Wire GlobeNews Wire

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

December 06, 2024 16:30 ET | Source: Tempest Therapeutics BRISBANE, Calif., Dec.…

GlobeNews Wire GlobeNews Wire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 03, 2024 16:05 ET | Source: X4 Pharmaceuticals BOSTON, Dec. 03,…

GlobeNews Wire GlobeNews Wire

Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq

Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq:…

GlobeNews Wire GlobeNews Wire